BaseSpace
Correlation
Engine-Public
Sign In
Register
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
Hypothalamus
,
Alcohol
,
Bleomycin
,
rs7903146
,
PPARA
,
Fatty acid metabolic process
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
TIE2
(gene)
Summary
General Info
Body Atlas
Most Correlated Tissues
Testis seminiferous tubule
Kidney
Lung
Uterus
Fetal lung
Explore Body Atlas Results
Disease Atlas
Most Correlated Diseases
Loading...
Explore Disease Atlas Results
Pharmaco Atlas
Most Correlated Compounds
Loading...
Explore Pharmaco Atlas Results
Knockdown Atlas
Most Correlated Gene Perturbations
Loading...
Explore Knockdown Atlas Results
Curated Studies
Most Correlated Studies
Loading...
Explore Curated Studies Results
Literature
Most Relevant Literature
Schlemm's canal-selective Tie2/TEK knockdown induces sustained ocular hypertension in adult mice.
Genetic association of TIE2 with diabetic retinopathy and diabetic macular edema.
The VALTIVE1 study protocol: a study for the validation of Tie2 as the first tumour vascular respons…
Angpt2/Tie2 autostimulatory loop controls tumorigenesis.
Elucidating the molecular basis of PECAM-1 and Tie2 interaction from binding dynamics and complex fo…
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
Validation of Tie2 as the First Tumour Vascular Response Biomarker for VEGF Inhibitors: VALTIVE1
Evaluation of the Predictive Value of Blood Levels of Angiopoietin 1 and Endothelial Internal Tunica…
A Study of ARRY-614 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome
A Study of ARRY-614 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes
ESK981 in Treating Patients With Metastatic Castrate-Resistant Prostate Cancer
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ